Karim Amighi is a pharmacist by training and obtained his PhD degree in pharmaceutical technology in 1995 from the Université libre de Bruxelles (ULB). He has been Professor and head of the Laboratory of Pharmaceutics and Biopharmaceutics since 2001 and occupied the position of Dean of the Faculty of Pharmacy (2011-2015) at the ULB.
His research interests are in the field of the formulation and evaluation of advanced drug delivery systems for oral, parenteral, pulmonary, and nasal routes of administration. He has published more than 100 peer-reviewed papers in internationally recognized journals, 120 abstracts and conference proceedings and filed 12 patents. He has supervised 35 PhD and post-doctorate students.
His research programme on lung drug delivery ranges from in vitro evaluation, to the evaluation of new excipients and/or devices, particle engineering and production using novel processes and aerosol formulation, and finally to scintigraphy imaging of lung deposition, local and systemic drug bioavailability and clinical outcomes.
He has been responsible for more than 40 competitive research projects, financed by regional funds or by national and international pharmaceuticals companies. He initiated a new spin-off company (InhaTarget Therapeutics) in the lung cancer targeted therapy field and, recently, the marketing of a new inhalation product for the treatment of COPD.